Pasireotide Diaspartate not checked
FollowEvery change as it happens, and a Monday email
Next date
None yet
Trials
3 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Somatostatin Analog FDA class
- Tested for
- Post-Bariatric Hypoglycemia
- Main trialPhase 2
- “The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).”In the company’s words, NCT05928390 on ClinicalTrials.gov
- Other names
- Pasireotide
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 29 Oct 2026 | Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia | |
| Phase 2Authorised | not given | Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PAMSARC) | |
| Phase 2Authorised | not given | Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026